Compared with other KRAS-driver mutations, such as G12-hotspot mutations, the Q61H mutation is rare (according to TCGA occurring in lung, colorectal, and pancreatic cancer in 0.2%, 0.7%, 2.8% of cases, respectively), which may explain why this immunogenic epitope has remained undetected so far (54). This evidence concerns the gene KRAS and pancreatic neoplasm.